876716-58-4

Basic information

• Product Name: 2-(3,5-DIMETHYLPIPERIDIN-1-YL)ETHANAMINE
• Synonyms: 2-(3,5-DIMETHYLPIPERIDIN-1-YL)ETHANAMINE;Albb-005694;2-(3,5-dimethylpiperidin-1-yl)ethanamine(SALTDATA: FREE);2-((3R,5S)-3,5-dimethylpiperidin-1-yl)ethan-1-amine
• CAS NO: 876716-58-4
• Molecular Formula: C9H20N2
• Molecular Weight: 156.27
• Mol File: 876716-58-4.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 208.1°C at 760 mmHg
• Flash Point: 77.3°C
• Appearance: /
• Density: 0.874g/cm³
• Vapor Pressure: 0.218mmHg at 25°C
• Refractive Index: 1.459
• PKA: 10.21±0.10(Predicted)
• CAS DataBase Reference: 2-(3,5-DIMETHYLPIPERIDIN-1-YL)ETHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,5-DIMETHYLPIPERIDIN-1-YL)ETHANAMINE(876716-58-4)
• EPA Substance Registry System: 2-(3,5-DIMETHYLPIPERIDIN-1-YL)ETHANAMINE(876716-58-4)

Safety Data

• Hazardous Substances Data: 876716-58-4(Hazardous Substances Data)

Usage

General Description

2-(3,5-Dimethylpiperidin-1-yl)ethanamine, also known as DMPEA, is a chemical compound with the molecular formula C10H21N. It is a tertiary amine derivative, and is commonly used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. DMPEA is also known for its stimulant and psychoactive effects, and is considered to be a psychoactive substance. It acts as a releasing agent for the neurotransmitters dopamine, norepinephrine, and serotonin in the brain, which can lead to mood elevation and increased alertness. However,

InChI:InChI=1/C9H20N2/c1-8-5-9(2)7-11(6-8)4-3-10/h8-9H,3-7,10H2,1-2H3

Upstream product

• 35794-11-7 3,5-dimethylpiperidine 
• 58861-74-8 2-bromoethylamine hydrochloride 
• 14446-75-4 (3S,5R)-3,5-dimethylpiperidine 

Relevant articles and documents

Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle

Reliance on hepatitis C virus (HCV) replicon systems and protein-based screening assays has led to treatments that target HCV viral replication proteins. The model does not encompass other viral replication cycle steps such as entry, processing, assembly and secretion, or viral host factors. We previously applied a phenotypic high-throughput screening platform based on an infectious HCV system and discovered an aryloxazole-based anti-HCV hit. Structure-activity relationship studies revealed several compounds exhibiting EC50 values below 100 nM. Lead compounds showed inhibition of the HCV pseudoparticle entry, suggesting a different mode of action from existing HCV drugs. Hit 7a and lead 7ii both showed synergistic effects in combination with existing HCV drugs. In vivo pharmacokinetics studies of 7ii showed high liver distribution and long half-life without obvious hepatotoxicity. The lead compounds are promising as preclinical candidates for the treatment of HCV infection and as molecular probes to study HCV pathogenesis.